The clinical state known as diabetes is characterized by hyperglycaemia brought on by an absolute or relative insulin shortage. The incidence and prevalence of diabetes mellitus have increased significantly in recent decades. The pharmaceutical industry frequently uses in vitro techniques for large-scale production. Because they are more affordable and easier to develop, they are favoured over animal approaches. Reducing the amount of glucose produced and absorbed in the gastrointestinal tract by inhibiting enzymes that break down carbohydrates, such as α-amylase, α-glucosidase, and α-amylase inhibition, is one method of treating diabetes. The postprandial rise in blood glucose following a mixed carbohydrate diet can be considerably reduced by inhibiting the amylase and glucosidase enzymes involved in the digestion of carbohydrates. As a result, inhibition of these enzymes can be a crucial tactic for blood glucose control. We have covered several in vitro tests in this study, including the α-amylase, α-glucosidase, PTP-1B, insulin secretion, and glucose uptake assays. In-vivo methods are too costly for evaluating hits. To carry out the necessary tasks and achieve the corresponding goals, it is now essential to design and execute appropriate in-vitro screening techniques.